We rely on peer-reviewed scientific research to determine what’s truly effective. Our goal is to provide clear, unbiased information to help you make better health decisions.
We use AI tools to help summarize studies, and every piece of content is reviewed and approved by qualified experts, ensuring it’s accurate and trustworthy.
Beta Glucan is fully independent — we don’t sell products, run ads, or accept sponsorships. Our only focus is delivering reliable, science-backed insights.
Key study details
Background
Beta glucans are well-established immunomodulators derived from sources such as yeast, mushrooms, and grains, with over 9,000 published studies supporting their biological effects. However, the market contains numerous glucan products differing in source, solubility, molecular weight, and purity, leading to inconsistent results in literature and clinical application. This study serves as a follow-up to previous comparative evaluations to determine if these diverse products offer comparable biological efficacy.
Objective
The study aimed to directly compare the immunological and anti-cancer activities of 15 new commercially available beta glucans from various international sources against a benchmark yeast-derived glucan (Glucan #300).
Methods
• Study Design: In vivo and in vitro comparative study.
• Population: Female BALB/c mice (8 weeks old).
• Duration: 14 days for the tumor model; acute (24–48 hours) for immune assays.
• Intervention: 16 different glucans (sourced from yeast, oat, barley, and mushrooms) injected intraperitoneally (i.p.). Doses ranged from 25 µg to 800 µg for phagocytosis assays and 100–200 µg for other assays.
• Primary and key secondary endpoints: Phagocytosis of synthetic microspheres, nitrite oxide production, IL-2 and IFN-γ secretion, and inhibition of Lewis lung carcinoma metastases.
Results
• Phagocytosis: Glucan #300 significantly stimulated phagocytosis at the lowest dose (25 µg). In contrast, approximately 30% of the other tested glucans showed no significant activity even at the highest dose (800 µg).
• Nitrite Oxide: Most glucans significantly stimulated nitrite oxide production compared to the PBS control. Glucan #300 (6.34 µmol/L), Yestimun (3.89 µmol/L), and Beta Glucan (2.78 µmol/L) were the most active.
• Cytokines: All glucans significantly increased IL-2 and IFN-γ secretion compared to the PBS control (which showed negligible basal levels). Glucan #300 elicited the highest response (IL-2: 828.7 pg/ml; IFN-γ: 198.2 pg/ml), followed by Yestimun and Reishi Mushroom Extract.
• Tumor Inhibition: Only four of the 16 tested samples (Glucan #300, Yestimun, Beta Glucan, and Beta 1,3/1,6-D-Glucan) significantly reduced the number of lung metastases in the Lewis lung carcinoma model. Glucan #300 reduced metastases to 11.7 ± 1.2 compared to 24.6 ± 2.1 in the control group.
Our take
Interpretation
The data supports the conclusion that not all beta glucans are biologically equivalent. Highly purified and active glucans exert strong, pleiotropic effects on both cellular and humoral immunity and cancer inhibition. However, many commercial samples showed limited or no activity, particularly in the suppression of cancer growth. There was no clear correlation between the biological activity and the source (yeast vs. mushroom vs. grain) or solubility of the glucan.
Mechanisms
The authors attribute the observed effects to the stimulation of cellular immunity, specifically the activation of professional phagocytes (macrophages and neutrophils). This activation leads to a respiratory burst (production of active oxygen species/nitrite oxide) and the secretion of cytokines (IL-2, IFN-γ), which regulate the immune response.
Dosage & Safety
Glucans were administered intraperitoneally. Doses for phagocytosis ranged from 25 µg to 800 µg; other assays used 100 µg or 200 µg per mouse. No specific adverse events were reported in the context of these experiments.
Study Quality
Strengths: Direct head-to-head comparison of a large number of commercial samples using identical experimental designs and multiple endpoints. Use of synthetic microspheres minimized false positives in phagocytosis assays. Limitations: The study utilized a mouse model with intraperitoneal administration, which may not directly translate to oral supplementation in humans.
Implications
This study adds to the evidence base that "beta glucan" is not a generic commodity; significant heterogeneity exists in the potency of commercial preparations. It highlights the necessity for verifying the biological activity of specific glucan products rather than relying on general literature claims.
This summary is based on peer-reviewed scientific research. We use AI tools to help condense complex studies, but all content is reviewed and approved by qualified experts before publication.
Citation
Copied!